

INTEGRA LIFESCIENCES HOLDINGS CORP

Reported by
CARUSO RICHARD E

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 03/12/18 for the Period Ending 03/08/18

Address	311 ENTERPRISE DRIVE PLAINSBORO, NJ, 08536
Telephone	6092750500
CIK	0000917520
Symbol	IART
SIC Code	3826 - Laboratory Analytical Instruments
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
CARUSO RICHARD E		INTEGRA LIFESCIENCES HOLDINGS CORP [IART]		<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last) (First) (Middle)		3. Date of Earliest Transaction (MM/DD/YYYY)			
795 E LANCASTER AVENUE, SUITE 200		3/8/2018			
(Street)		4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)	
VILLANOVA, PA 19085				<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	3/8/2018		M		12002	A	\$18.06	146136 (1)	D	
Common Stock	3/8/2018		S		12002	D	\$53.6819 (2)	134134	D	
Common Stock	3/8/2018		M		20878	A	\$18.06	155012	D	
Common Stock	3/8/2018		S		20878	D	\$53.6819 (2)	134134	D	
Common Stock								46676	I	By Corporation
Common Stock								11982410	I	By Partnership
Common Stock								4000	I	By Son

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$18.06	3/8/2018		M		12002		(3)	5/19/2018	Common Stock	12002	\$0.00	0 (4)(5)	D	
Non-Qualified Stock Option (right to buy)	\$18.06	3/8/2018		M		20878		(3)	5/19/2018	Common Stock	20878	\$0.00	0 (5)(6)	D	

Explanation of Responses:

- On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4.
- The price shown above represents the weighted average price of the shares sold. The range of sale prices was \$53.37 to \$54.
- 25% of the stock options vest every quarter from the grant date of 5/19/2010
- This option was previously reported as covering 5,749 shares at an exercise price of \$41.75 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015 to 6,001 shares of common stock at an exercise price of \$36.12 per share.
- In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016.
- This option was previously reported as covering 10,000 shares at an exercise price of \$41.75 per share, but was adjusted pursuant to the anti-dilution

provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015 to 10,439 shares of common stock at an exercise price of \$36.12 per share.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CARUSO RICHARD E 795 E LANCASTER AVENUE, SUITE 200 VILLANOVA, PA 19085		X		

Signatures

/s/ Dr. Richard E. Caruso

3/12/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.